文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

哌拉西林-他唑巴坦与头孢西丁作为胰十二指肠切除术抗菌预防的比较:一项随机临床试验

Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论开放胰十二指肠切除术围术期用哌拉西林-他唑巴坦预防,较头孢西丁降低30天手术部位感染(19.8% vs 32.8%),作者支持将其作为标准预防。

这项在美加26家医院开展的实用、开放标签、多中心、随机3期试验,纳入778例因任何指征行开放胰十二指肠切除术的成人,1:1随机接受哌拉西林-他唑巴坦(3.375或4 g静脉)或头孢西丁(2 g静脉)围术期预防。30天手术部位感染率哌拉西林-他唑巴坦组19.8% vs 头孢西丁组32.8%(绝对差-13.0%,95%CI -19.1%至-6.9%,P<.001)。术后脓毒症(4.2% vs 7.5%,P=.02)和临床相关术后胰瘘(12.7% vs 19.0%,P=.03)也更低;30天死亡率无显著差异(1.3% vs 2.5%,P=.32)。作者认为 findings 支持将哌拉西林-他唑巴坦作为开放胰十二指肠切除术的标准预防。

要点

  • 开放胰十二指肠切除术围术期预防用哌拉西林-他唑巴坦(3.375或4 g静脉)较头孢西丁(2 g静脉)降低30天SSI:19.8% vs 32.8%,绝对差-13.0%(95%CI -19.1%至-6.9%),P<.001。
  • 哌拉西林-他唑巴坦组术后脓毒症4.2% vs 头孢西丁组7.5%,差-3.3%(95%CI -6.6%至0.0%),P=.02。
  • 临床相关术后胰瘘哌拉西林-他唑巴坦组12.7% vs 头孢西丁组19.0%,差-6.3%(95%CI -11.4%至-1.2%),P=.03。
  • 30天死亡率哌拉西林-他唑巴坦组1.3%(5/378)vs 头孢西丁组2.5%(10/400),差-1.2%(95%CI -3.1%至0.7%),P=.32,无显著差异。
  • 作者认为 findings 支持将哌拉西林-他唑巴坦作为开放胰十二指肠切除术的标准预防。

适用人群与场景

  • 因任何指征行开放胰十二指肠切除术的成人;2017年11月至2021年8月入组,随访至2021年12月。
  • 排除:对研究药物过敏、活动性感染、长期使用类固醇、显著肾功能不全、妊娠或哺乳期。

处置流程与药物剂量

  • 干预组:哌拉西林-他唑巴坦3.375或4 g静脉,作为围术期抗菌预防。
  • 对照组:头孢西丁2 g静脉(标准治疗)。

研究设计与关键结果

  • 设计:实用、开放标签、多中心、随机3期试验,26家医院(美国与加拿大),1:1区组随机,按术前胆道支架分层;参与者、研究者与统计人员均非盲。
  • 样本量:778例(哌拉西林-他唑巴坦组378例,中位年龄66.8岁,男性233例[61.6%];头孢西丁组400例,中位年龄68.0岁,男性223例[55.8%])。
  • 主要终点30天SSI:哌拉西林-他唑巴坦组19.8% vs 头孢西丁组32.8%,绝对差-13.0%(95%CI -19.1%至-6.9%),P<.001。
  • 术后脓毒症:哌拉西林-他唑巴坦组4.2% vs 头孢西丁组7.5%,差-3.3%(95%CI -6.6%至0.0%),P=.02。
  • 临床相关术后胰瘘:哌拉西林-他唑巴坦组12.7% vs 头孢西丁组19.0%,差-6.3%(95%CI -11.4%至-1.2%),P=.03。
  • 30天死亡率:哌拉西林-他唑巴坦组1.3%(5/378)vs 头孢西丁组2.5%(10/400),差-1.2%(95%CI -3.1%至0.7%),P=.32。
  • 试验基于预设停止规则在中期分析时终止。

证据类型、等级与局限

  • 证据类型:随机3期临床试验(实用、开放标签、多中心)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,开放胰十二指肠切除术围术期预防使用哌拉西林-他唑巴坦可降低术后SSI、胰瘘及SSI的多种下游后果,支持将其作为开放胰十二指肠切除术的标准预防。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Despite improvements in perioperative mortality, the incidence of postoperative surgical site infection (SSI) remains high after pancreatoduodenectomy. The effect of broad-spectrum antimicrobial surgical prophylaxis in reducing SSI is poorly understood.

OBJECTIVE: To define the effect of broad-spectrum perioperative antimicrobial prophylaxis on postoperative SSI incidence compared with standard care antibiotics.

DESIGN, SETTING, AND PARTICIPANTS: Pragmatic, open-label, multicenter, randomized phase 3 clinical trial at 26 hospitals across the US and Canada. Participants were enrolled between November 2017 and August 2021, with follow-up through December 2021. Adults undergoing open pancreatoduodenectomy for any indication were eligible. Individuals were excluded if they had allergies to study medications, active infections, chronic steroid use, significant kidney dysfunction, or were pregnant or breastfeeding. Participants were block randomized in a 1:1 ratio and stratified by the presence of a preoperative biliary stent. Participants, investigators, and statisticians analyzing trial data were unblinded to treatment assignment.

INTERVENTION: The intervention group received piperacillin-tazobactam (3.375 or 4 g intravenously) as perioperative antimicrobial prophylaxis, while the control group received cefoxitin (2 g intravenously; standard care).

MAIN OUTCOMES AND MEASURES: The primary outcome was development of postoperative SSI within 30 days. Secondary end points included 30-day mortality, development of clinically relevant postoperative pancreatic fistula, and sepsis. All data were collected as part of the American College of Surgeons National Surgical Quality Improvement Program.

RESULTS: The trial was terminated at an interim analysis on the basis of a predefined stopping rule. Of 778 participants (378 in the piperacillin-tazobactam group [median age, 66.8 y; 233 {61.6%} men] and 400 in the cefoxitin group [median age, 68.0 y; 223 {55.8%} men]), the percentage with SSI at 30 days was lower in the perioperative piperacillin-tazobactam vs cefoxitin group (19.8% vs 32.8%; absolute difference, -13.0% [95% CI, -19.1% to -6.9%]; P < .001). Participants treated with piperacillin-tazobactam, vs cefoxitin, had lower rates of postoperative sepsis (4.2% vs 7.5%; difference, -3.3% [95% CI, -6.6% to 0.0%]; P = .02) and clinically relevant postoperative pancreatic fistula (12.7% vs 19.0%; difference, -6.3% [95% CI, -11.4% to -1.2%]; P = .03). Mortality rates at 30 days were 1.3% (5/378) among participants treated with piperacillin-tazobactam and 2.5% (10/400) among those receiving cefoxitin (difference, -1.2% [95% CI, -3.1% to 0.7%]; P = .32).

CONCLUSIONS AND RELEVANCE: In participants undergoing open pancreatoduodenectomy, use of piperacillin-tazobactam as perioperative prophylaxis reduced postoperative SSI, pancreatic fistula, and multiple downstream sequelae of SSI. The findings support the use of piperacillin-tazobactam as standard care for open pancreatoduodenectomy.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03269994.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. D'Angelica MI, Ellis RJ, Liu JB, et al. Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. JAMA. 2023. PMID: 37078771. doi:10.1001/jama.2023.5728

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。